Avid Bioservices (CDMO)
(Delayed Data from NSDQ)
$6.83 USD
+0.15 (2.25%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $6.82 -0.01 (-0.15%) 7:58 PM ET
5-Strong Sell of 5 5
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CDMO 6.83 +0.15(2.25%)
Will CDMO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CDMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDMO
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
CDMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
Other News for CDMO
Avid Bioservices Q3 Financial Results Conference Call Announcement
Avid Bioservices misses top-line and bottom-line estimates; reaffirms FY24 outlook
Avid Bioservices: Fiscal Q3 Earnings Snapshot
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
CDMO Stock Earnings: Avid Bioservices Misses EPS, Beats Revenue for Q3 2024